BioSpace News Archive

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022 at 4:00 pm ET.

Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET.

Chimerix announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright Global Investment Conference made available on Tuesday, May 24, 2022 at 7:00 a.m. ET.

Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.

NANOBIOTIX announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the Jefferies Healthcare Conference in June 2022.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx

EDAP TMS SA, a global leader in robotic energy-based therapies, announced unaudited financial results for the first quarter 2022.

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences.

Travere Therapeutics, Inc. announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy and focal segmental glomerulosclerosis, respectively, at the 59th European Renal Association Congress.